Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03739606
Title Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications
Therapies
Age Groups: adult | child | senior
Covered Countries

Facility Status City State Zip Country Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field